Are Drug-Eluting Stents Safe in the Long Term After Saphenous Vein Graft Intervention? Lessons Learned From Real-World Practice∗ by Stefanadis, Christodoulos
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 4 , N O . 1 7 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 7 . 9 8 0EDITORIAL COMMENTAre Drug-Eluting Stents Safe in the
Long Term After Saphenous Vein
Graft Intervention?
Lessons Learned From Real-World Practice*Christodoulos Stefanadis, MDSEE PAGE 1825A lmost 2.5 millennia ago, Hippocrates pub-lished his famous quote: “As to diseases,make a habit of 2 things—to help or to do
no harm.” In modern medicine, this issue remains
in the spotlight as new therapies are introduced into
clinical practice. An excellent example of promising
efﬁcacy results being overshadowed by safety con-
cerns was the introduction of drug-eluting stents
(DES), which were intended to reduce the need for
repeat vascularization. Initial enthusiasm about the
increased efﬁcacy of DES (1,2) soon gave way to safety
concerns after the Swedish Coronary Angiography
and Angioplasty Registry (SCAAR) published a report
of a possible late excess mortality risk with DES (3).
Fortunately, these concerns were disproved by large
studies with long-term follow-up that demonstrated
the long-term safety and efﬁcacy of DES (4,5).
Concerns similar to those regarding the use of DES
in native coronary arteries were expressed for
percutaneous coronary intervention (PCI) of failing
saphenous vein grafts (SVGs). SVG atherosclerosis
is a pathological entity with similarities to native
atherosclerosis but with important differences in
terms of both pathological substrate and treatment.
Contrary to native atherosclerosis, where lesions such
as ﬁbroatheromas comprise the dominant pathology
(6), SVGs accumulate large quantities of degenerated
atheromatous and thrombotic debris (7), leading to*Editorials published in the Journal of the American College of Cardiology
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gression and impaired healing after stent implanta-
tion is also frequently observed (9), resulting in high
rates of stent failure and repeat intervention (10,11).
This is the reason that DES held high promises as a
therapy that would potentially reduce these high
rates of repeat revascularization. However, as in
native atherosclerosis, safety concerns were raised
due to the ﬁnding of increased late mortality in a
small randomized clinical trial of DES versus bare
metal stents (BMS) (12). Subsequent registry and
randomized studies did not conﬁrm this ﬁnding
(13,14), while the most convincing evidence arose
from a large randomized clinical trial showing
increased efﬁcacy of DES without differences in 1-
year safety endpoints (15). Results of that study and
of subsequent meta-analyses succeeded in appeasing
these initial concerns about DES safety in SVG-PCI,
without, however, providing deﬁnite answers for
long-term safety.In light of these inconclusive data, Aggarwal et al.
(16), in this issue of the Journal, report on their
ﬁndings from a real-world registry, focusing on late
safety outcomes in SVG-PCI. The authors present
ﬁndings from a national cohort of 2,471 patients
undergoing SVG-PCI at Veterans Affairs hospitals
between 2008 and 2011, examining differences in
procedural outcomes and late safety endpoints,
namely myocardial infarction and all-cause mortality,
between patients receiving DES and those receiving
BMS. Data from this registry demonstrate a contin-
uous increase in the percentage of DES used in SVG-
PCI from 50% in 2008 to 69% in 2011, potentially
reﬂecting physicians’ reassurance about the safety
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1838of DES from the accumulating body of evidence
from SVG-PCI trials and all-comer populations. As in
previous studies (13,14), acute safety data from this
study demonstrate similar incidence rates of in-
hospital complications between BMS and DES. Addi-
tionally, a lower incidence of no-reﬂow and vessel
perforation was observed for DES, attributed mainly
to potential procedural confounders. Analysis of
long-term safety endpoints in a propensity-matched
population showed similar rates of myocardial in-
farction in DES and BMS (5.8% for DES vs. 7.5% for
BMS at 1 year; hazard ratio [HR]: 0.94; 95% conﬁ-
dence interval [CI]: 0.71 to 1.24) and lower all-cause
mortality in the group of DES patients (8.4% vs.
11.3% at 1 year, respectively; HR: 0.72; 95% CI: 0.57 to
0.89), remaining signiﬁcant after adjustment for
lesion-level characteristics.
To supplement current knowledge about late DES
safety in SVG-PCI, this well-conducted study takes
advantage of the knowledge of the vital status in a
large population treated with DES or BMS for SVG-
PCI. Previous ﬁndings of similar mortality rates be-
tween DES and BMS in SVG-PCI are corroborated and
extended to a mean follow-up of 33 months. Im-
portantly, in contrast to previous studies performed
mainly with ﬁrst-generation DES, second-generation
DES were used in almost two-thirds of the DES-
treated population in this study. This observation
supports the safety of second-generation DES in SVG-
PCI, consistent with clinical observations that these
stents have an enhanced safety proﬁle in native
vessel PCI (17) and with imaging observations of a
favorable healing response (18).
Although this study provides some reassuring
ﬁndings about late DES safety in SVG-PCI, there are
still several unanswered questions. Due to the lack ofdata for cardiac mortality, the lack of routine clinical
follow-up hampers a comprehensive assessment of
clinical outcome. Moreover, the dual antiplatelet
therapy status of patients in this registry is unknown;
thus, the contribution of different antiplatelet stra-
tegies could not be evaluated. In the absence of
conﬁrmatory randomized data, the lower mortality
rate observed with DES should, therefore, be inter-
preted with caution and regarded as an unproven
hypothesis. Moreover, the lack of angiographic
follow-up does not allow the late behavior of DES
implanted for treatment of SVG disease to be eluci-
dated. This is an important issue that remains unad-
dressed, as previous reports revealed the possible
presence of a late “catch-up” phenomenon, with no
differences in repeat revascularization rates with
longer-term follow-up (14,19,20), contradicting other
studies that showed a sustained beneﬁt for DES (21).
These issues remain to be clariﬁed by adequately
powered randomized trials that include long-term
follow-up and that are able to investigate the
impact of different antiplatelet regimens, thus
addressing late safety and efﬁcacy issues. However,
the contribution of studies like that of Aggarwal
et al. (16) should not be neglected; such real-world
registries are important for evaluating whether clin-
ical practice is, indeed, moving on the right track and
for providing large-scale observations that corrobo-
rate and supplement ﬁndings from randomized
studies.
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